Why Sandoz Appeal To High Court Is Important For Biosimilars

Law360, New York (February 22, 2016, 10:04 AM ET) -- Robert Colletti



Daniel Worley As many expected, Sandoz Inc. filed a petition for a writ of certiorari asking the U.S. Supreme Court to review the Federal Circuit’s decision in Amgen Inc. v. Sandoz Inc.[1],[2] Amgen will have an opportunity to not only oppose Sandoz’s petition but also to file a conditional cross petition.[3] Amgen is the first Federal Circuit decision to substantively interpret the Biologics Price Competition and Innovation Act of 2009, so whether the court decides to hear the case will be closely monitored by...

To view the full article, register now.